A detailed history of Lipe & Dalton transactions in Eli Lilly & CO stock. As of the latest transaction made, Lipe & Dalton holds 45 shares of LLY stock, worth $33,975. This represents 0.02% of its overall portfolio holdings.

Number of Shares
45
Previous 56 19.64%
Holding current value
$33,975
Previous $51,000 21.57%
% of portfolio
0.02%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$772.14 - $960.02 $8,493 - $10,560
-11 Reduced 19.64%
45 $40,000
Q1 2024

May 07, 2024

BUY
$592.2 - $792.28 $6,514 - $8,715
11 Added 24.44%
56 $44,000
Q4 2023

Jan 30, 2024

BUY
$525.19 - $619.13 $23,633 - $27,860
45 New
45 $26,000
Q1 2021

Apr 30, 2021

SELL
$164.32 - $212.72 $16,432 - $21,272
-100 Closed
0 $0
Q3 2019

Nov 07, 2019

SELL
$106.79 - $116.16 $1,067 - $1,161
-10 Reduced 9.09%
100 $11,000
Q1 2019

Apr 30, 2019

BUY
$111.31 - $131.02 $12,244 - $14,412
110 New
110 $14,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $717B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Lipe & Dalton Portfolio

Follow Lipe & Dalton and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lipe & Dalton, based on Form 13F filings with the SEC.

News

Stay updated on Lipe & Dalton with notifications on news.